相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
N. Harbeck et al.
ANNALS OF ONCOLOGY (2021)
Commentary: SARS-CoV-2 vaccines and cancer patients
C. Corti et al.
ANNALS OF ONCOLOGY (2021)
Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box
Paolo Tarantino et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2021)
Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer
R. Connor Chick et al.
CLINICAL IMMUNOLOGY (2021)
Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis
U. Dafni et al.
EUROPEAN JOURNAL OF CANCER (2021)
AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence
Patrick M. McCarthy et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
SARS-CoV-2 vaccines for cancer patients: a call to action
Chiara Corti et al.
EUROPEAN JOURNAL OF CANCER (2021)
Syndecan-1 (CD138), Carcinomas and EMT
John R. Couchman
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
The Immunology of Hormone Receptor Positive Breast Cancer
Jonathan Goldberg et al.
FRONTIERS IN IMMUNOLOGY (2021)
Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer
C. Corti et al.
ESMO OPEN (2021)
Therapeutic cancer vaccines revamping: technology advancements and pitfalls
G. Antonarelli et al.
ANNALS OF ONCOLOGY (2021)
Managing side effects of immune checkpoint inhibitors in breast cancer
Carmen Criscitiello et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
Final five-year median follow-up safety data from a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase IIb study evaluating the use of HER2/neu peptide GP2+GMCSF vs. GM-CSF alone after adjuvant trastuzumab in HER2-positive women with operable breast cancer.
Snehal Patel et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Antibody-Drug Conjugates for the Treatment of Breast Cancer
Chiara Corti et al.
CANCERS (2021)
Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer
Peter M. K. Westcott et al.
NATURE CANCER (2021)
Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy
Jason I. Griffiths et al.
NATURE CANCER (2021)
Breast cancer vaccines: Heeding the lessons of the past to guide a path forward
Cinzia Solinas et al.
CANCER TREATMENT REVIEWS (2020)
HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development
Atefeh Arab et al.
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS (2020)
Expression of tumor-associated antigens in breast cancer subtypes
Giuseppe Curigliano et al.
BREAST (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients
Pierre Rosenbaum et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Results of a Randomized Phase IIb Trial of Nelipepimut-S thorn Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer
G. Travis Clifton et al.
CLINICAL CANCER RESEARCH (2020)
DC-CIK as a widely applicable cancer immunotherapy
Shuo Wang et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence
Tommy A. Brown et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk for recurrence.
Hope S. Rugo et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
ESR1 mutations provide novel targets for breast cancer immunotherapy.
Jonathan Goldberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials
Nicholas C. Turner et al.
CLINICAL CANCER RESEARCH (2020)
Tumor-infiltrating lymphocytes (TILs) in ER+/HER2-breast cancer
C. Criscitiello et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study
Chiun-Sheng Huang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Roles of NK Cell Receptors 2B4 (CD244), CS1 (CD319), and LLT1 (CLEC2D) in Cancer
Casey W. Buller et al.
CANCERS (2020)
Bacterial and viral vectors as vaccine delivery vehicles for breast cancer therapy
Balamurugan Shanmugaraj et al.
LIFE SCIENCES (2020)
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
Daniel K. Wells et al.
CELL (2020)
Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond
Ricardo L. B. Costa et al.
NPJ BREAST CANCER (2020)
The role of WT1 in breast cancer: clinical implications, biological effects and molecular mechanism
Ye Zhang et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2020)
Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients
Nadine Norton et al.
NPJ BREAST CANCER (2020)
Signaling pathway of globo-series glycosphingolipids and β1,3-galactosyltransferase V (β3GalT5) in breast cancer
Po-Kai Chuang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial
Elizabeth A. Mittendorf et al.
CLINICAL CANCER RESEARCH (2019)
Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis
Fabio Conforti et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Prevalence and role of HER2 mutations in cancer
Emiliano Cocco et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Current Landscape of Immunotherapy in Breast Cancer: A Review
Sylvia Adams et al.
JAMA ONCOLOGY (2019)
Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer
Funda Meric-Bernstam et al.
CLINICAL CANCER RESEARCH (2019)
Targeting the microenvironment in solid tumors
Carmen Belli et al.
CANCER TREATMENT REVIEWS (2018)
Developing anti-HER2 vaccines: Breast cancer experience
Aydah Al-Awadhi et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
A phase 1 study of p53MVA vaccine in combination with pembrolizumab.
Vincent M. Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert et al.
LANCET ONCOLOGY (2018)
DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer
Na Luo et al.
NATURE COMMUNICATIONS (2018)
SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Acticates CD4+ T Lymphocytes
Markus D. Lacher et al.
FRONTIERS IN IMMUNOLOGY (2018)
Breast cancer stem cell autoantibodies to identify women with advanced breast cancer.
Sasha E. Stanton et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Targeting mutant p53 for efficient cancer therapy
Vladimir J. N. Bykov et al.
NATURE REVIEWS CANCER (2018)
Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth
Paul D. Bryson et al.
VACCINE (2017)
Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects
Laura F. Hutchins et al.
ONCOTARGET (2017)
The clinical development of vaccines for HER2+ breast cancer: Current landscape and future perspectives
R. L. B. Costa et al.
CANCER TREATMENT REVIEWS (2017)
Immunotherapy for Breast Cancer: Current and Future Strategies
Austin D. Williams et al.
CURRENT SURGERY REPORTS (2017)
Immunogenic cell death in cancer and infectious disease
Lorenzo Galluzzi et al.
NATURE REVIEWS IMMUNOLOGY (2017)
The genomic landscape of breast cancer and its interaction with host immunity
Stephen Luen et al.
BREAST (2016)
A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer
Giuseppe Curigliano et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
The fully synthetic MAG-Tn3 therapeutic vaccine containing the tetanus toxoid-derived TT830-844 universal epitope provides anti-tumor immunity
Daphne Laubreton et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
The development and use of the E75 (HER2 369-377) peptide vaccine
Guy T. Clifton et al.
FUTURE ONCOLOGY (2016)
Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential
Lucy M. De La Cruz et al.
IMMUNOTHERAPY (2016)
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
Brian I. Rini et al.
LANCET ONCOLOGY (2016)
Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study
H. Raza Ali et al.
PLOS MEDICINE (2016)
Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond
Cristina Migali et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2016)
Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes A Systematic Review
Sasha E. Stanton et al.
JAMA ONCOLOGY (2016)
Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer Role for Immune Monitoring
Jashodeep Datta et al.
JAMA ONCOLOGY (2016)
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials
M. V. Dieci et al.
ANNALS OF ONCOLOGY (2015)
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
Emanuele Valtorta et al.
MODERN PATHOLOGY (2015)
Natural and therapy-induced immunosurveillance in breast cancer
Guido Kroemer et al.
NATURE MEDICINE (2015)
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab A Secondary Analysis of the NeoALTTO Trial
Roberto Salgado et al.
JAMA ONCOLOGY (2015)
Classical pathology and mutational load of breast cancer - integration of two worlds
Jan Budczies et al.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2015)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S. Loi et al.
ANNALS OF ONCOLOGY (2014)
The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis
Ezzeldin M. Ibrahim et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Current status of autologous breast tumor cell-based vaccines
Samantha L. Kurtz et al.
EXPERT REVIEW OF VACCINES (2014)
Dendritic cell-based vaccines: clinical applications in breast cancer
Lucia Gelao et al.
IMMUNOTHERAPY (2014)
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
Gary Middleton et al.
LANCET ONCOLOGY (2014)
DNA vaccine for cancer immunotherapy
Benjamin Yang et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
A phase I trial of the safety and immunogenicity of a DNA-based vaccine encoding the HER2/neu (HER2) intracellular domain in subjects with HER2+breast cancer.
Mary L. Disis et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Pathways of Antigen Processing
Janice S. Blum et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses
Y. Xie et al.
CANCER GENE THERAPY (2013)
Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation
Rodney A. Rosalia et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2013)
MHC Class I Antigen Processing and Presenting Machinery: Organization, Function, and Defects in Tumor Cells
Patrizia Leone et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors
Claudia Marcela Diaz-Montero et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence et al.
NATURE (2013)
Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer - A Substudy of the Neoadjuvant GeparQuinto Trial
Yasmin Issa-Nummer et al.
PLOS ONE (2013)
Tailoring DNA vaccines: designing strategies against HER2-positive cancers
Cristina Marchini et al.
FRONTIERS IN ONCOLOGY (2013)
Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer
Makiko Ono et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
The future of human DNA vaccines
Lei Li et al.
JOURNAL OF BIOTECHNOLOGY (2012)
Design considerations for liposomal vaccines: Influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens
Douglas S. Watson et al.
VACCINE (2012)
Cancer immunotherapy via dendritic cells
Karolina Palucka et al.
NATURE REVIEWS CANCER (2012)
Viral Vector-Based Therapeutic Cancer Vaccines
Cecilia Larocca et al.
CANCER JOURNAL (2011)
HER2 genetic heterogeneity in breast carcinoma
Christian Oehlschlegel et al.
JOURNAL OF CLINICAL PATHOLOGY (2011)
Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer
David Miles et al.
ONCOLOGIST (2011)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial
Hakan Norell et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators
Pernille Nordly et al.
EXPERT OPINION ON DRUG DELIVERY (2009)
Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation
Leisha A. Emens et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel
Shinichi Kageyama et al.
CANCER SCIENCE (2008)
High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates
Gabricla Alexe et al.
CANCER RESEARCH (2007)
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis
M. M. Moasser
ONCOGENE (2007)
Treatment with autologous antigen-presenting cells activated with the HER-2-based antigen lapuleucel-T: Results of a phase I study in immunologic and clinical activity in HER-2-overexpressing breast cancer
John W. Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination
Teresa Cabrera et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion
Brian J. Czerniecki et al.
CANCER RESEARCH (2007)
Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells
Silke Holtkamp et al.
BLOOD (2006)
HER2-specificT-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan
Shigehisa Kitano et al.
CLINICAL CANCER RESEARCH (2006)
Breast cancer vaccines: a clinical reality or fairy tale?
G Curigliano et al.
ANNALS OF ONCOLOGY (2006)
A Tat fusion protein-based tumor vaccine for breast cancer
CT Viehl et al.
ANNALS OF SURGICAL ONCOLOGY (2005)
Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma
K Mimura et al.
BRITISH JOURNAL OF CANCER (2005)
Effect of dose on immune response in patients vaccinated with an HER-2/neu intracellular domain protein-based vaccine
ML Disis et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
CL Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
分享论文
